

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

(COMPANY LIMITED BY GUARANTEE)


COMPANY REGISTRATION NUMBER 4307833

COMPANY CHARITY NUMBER: 1103852

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

WEDNESDAY



"AGXVR12C"

A35

02/07/2008

479

COMPANIES HOUSE

Verinder and Associates
Chartered Accountants

1 – 3 Crosby Road South
Liverpool, L22 1RG

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

Contents	Pages
Trustees' Report	1 - 5
Independent auditors' report	6
Statement of financial activities	7
Balance Sheet	8
Notes to financial statements	9 - 13

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

TRUSTEES' REPORT

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

The Trustees have pleasure in presenting their report and the audited financial statements of the charity for the year ended 30th September 2007. The financial statements have been prepared in accordance with the Statement of Recommended Practice – Accounting and Reporting by Charities issued in October 2005.

Reference and Administrative Details

Charity Name	British Neuroscience Association Limited
Charity Registration Number	1103852
Company Registration Number	4307833

Members of the Committee

Prof Graham Collingridge (President, from January 2007)
Prof Richard Frackowiak - (retired President, January 2007)
Dr Stefan Przyborski - (Treasurer)
Prof Mike Stewart
Prof Colin Ingram
Dr Duncan Banks
Dr Vincent O'Connor
Dr Mike O'Neill (retired June 2007)
Prof Andrew King (retired June 2007)
Dr Narendra Ramnani (co-opted June 2007)
Prof Helen Hodges
Prof Judith Pratt
Dr Mike Rigby
Prof Bruno Frenguelli (elected June 2007)
Dr Lucy Annett (elected June 2007)

Honorary Secretary

Dr Debbie Dewar (retired April 2007)
Prof Colin Ingram (from April 2007)

Executive Secretary

Dr Y Allen

Administrator

Ms Samantha Potts (until June 2007)
Ms Dawn Roberts (from June 2007)

Registered Office

Sherrington Buildings
Ashton Street
Liverpool
L69 3GE

Auditors

Verinder and Associates
1-3 Crosby Road South
Liverpool
L22 1RG

Bankers

Barclays Bank Plc
4 Water Street
Liverpool L4

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

TRUSTEES' REPORT

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

Structure, governance and management

British Neuroscience Association Limited was incorporated on 19th October 2001 (Company registration 4307833) On 1st March 2005, all of the assets and activities of British Neuroscience Association (formerly Brain Research Association), an associated charity (Charity registered No 264450), were transferred to British Neuroscience Association Limited British Neuroscience Association Limited is a company limited by guarantee and is governed by its Memorandum and Articles of Association as amended by special resolution on 17th December 2003 The Company was registered as a charity on 20th May 2004 under the registration number 1103852

The trustees who have served during the year are set out below The president, treasurer and honorary secretary of the committee of the association are the trustees Trustees hold office for a period of three years, but may in exceptional circumstances be elected for a further year

The committee consists of nine members of the association elected by the national membership, by postal ballot, and one representative co-opted by the committee for their specialist skills and knowledge The committee has the power to co-opt a maximum of three members Nationally elected members hold office until the end of the third year following the ballot in which they were elected The period of co-opting is two years

The committee meets every three months and additionally as required

The Trustees

The trustees who served the charity during the period were as follows

Prof Graham Collingridge (President)
Prof Colin Ingram (Honorary Secretary)
Dr Stefan Przyborski (Honorary Treasurer)

Objectives and activities

The Association's objects (The Objects) are as follows

- a) To promote on a multidisciplinary basis the study of the development structure and function of the nervous system in health and disease
- b) To promote the dissemination of information to all those interested in the neurosciences and related disciplines by means of lectures, discussions, meetings and reports from time to time obtained from such researchers
- c) To advise as far as possible on issues in neurosciences related to health and disease
- d) To endeavour to increase public awareness and understanding of neuroscience research in health and disease
- e) To assist in the training of neuroscientists and other professionals engaged in neuroscience teaching and research

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

TRUSTEES' REPORT

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

Achievements and performance

The year from September 2006 to 2007 was particularly busy and more challenging than ever as the BNA not only hosted its own national meeting during this period but also embarked on new collaborative ventures with the Wellcome Trust (a series of Masterclasses in clinical neurosciences) and with the *Glial Cells in Health and Disease* biennial European meeting. These events were in addition to our continuing series of public discussions at the Dana Centre in London, and our themed One-Day symposia, including the very popular annual Christmas Symposium.

The year began, however, with the BNA attending the American Society for Neuroscience meeting in Atlanta, Georgia, in October. Our booth was regularly visited by BNA members and new contacts alike, interested especially in attending our national meeting the following spring.

The first of our One-Day themed symposia was hosted in Oxford in early November, and addressed the role of invertebrate studies in elucidating 'Genes and Synapses'. The second of these was held in May at the Open University as part of the Pro-Memoria series, focusing on 'Functional Cellular Neuroimaging and Microscopy'. This was also a tremendous success, involving many European delegates, many of whom then enjoyed the practical component of the course that continued in London the following day. By the end of the year, plans were well underway for another One-Day symposium, this time on stroke, to be held at the Royal Society of Edinburgh in the autumn, in collaboration with the Scottish Stroke Network.

Our popular, and always well-supported, annual Christmas Symposium was again held at the Royal Society in London and celebrated the contribution of Cajal and Golgi to neurobiology upon the centenary of their jointly awarded Nobel prize for medicine in 1906. At this meeting, the BNA was honoured to present its *Public Service Award* for 2006 to Mike Robbins. Mike Robbins has campaigned tirelessly for many years for a better understanding of 'deep brain stimulation' as a treatment for parkinsonism and dystonia, and for better appreciation of the role that animal studies have played in its development. The BNA Award for *Outstanding Contribution to British Neuroscience* was, on the same occasion, awarded to Horace Barlow for his elucidating work over many decades on visual processing. A brief AGM (postponed from the summer) was also held at the Royal Society in December, where nearly 150 members were able to receive and comment on reports from the Trustees.

Continuing an important collaboration with the European Dana Alliance for the Brain (EDAB), the BNA hosted two public discussions at the Dana Centre, London, on themes considered to be topical and controversial. The first, in June, examined the efficacy of 'talking therapies', and considered the neurobiological changes in the brain, if any, after such intervention, the second, in September, was entitled 'Mind Wars' and explored 'bioterrorism' in general and the exploitation of brain research for military purposes. As always, these were both well supported and much appreciated by our members and the public alike.

Most importantly, however, the year was dominated by our 19th National Meeting in Harrogate in April that attracted over 600 attendees, including many from Ireland as the meeting was hosted in collaboration with the newly inaugurated *Neuroscience Ireland*. Delegates enjoyed seven fine plenary lectures, over 20 symposia and 50 themed poster sessions. There was also an exhibition involving 35 companies and a wide range of peripheral events examining the role of the media, for instance, in communicating science, and another event that explored the general concept of the 'Art-Science Divide'. At the AGM, also hosted in Harrogate, members endorsed the possibility of returning to this attractive location for the 20th meeting in 2009.

As the national meeting drew to a close, the BNA was already heavily involved in the final throes of another major meeting – the biennial *VIIIth European Glial Cells in Health and Disease* meeting, held in early September and hosted in the UK (Imperial College, London) for the first time ever. The scientific programme was spear-headed by long-standing BNA members, Professors Kris Jessen, Rhona Mirsky and Richard Reynolds, and was clearly instrumental in attracting over 750 delegates to the meeting, making it the most successful in the series so far.

Soon after this event, the BNA launched the pilot series of *Wellcome Trust Masterclasses in Clinical Neuroscience* by organising the very first one, focussing on the role of restorative neuroscience in stroke rehabilitation. By the end of September, plans were already underway to continue this series in 2008, addressing on this occasion the major controversies in motor neuron disease research and practice. This will be held in May at the same venue (Cumberland Lodge, Windsor Great Park).

During the year, the BNA continued its commitment to its younger researchers by awarding bursaries to attend the national meeting in Harrogate, and by supporting financially a special postgraduate symposium in Bristol. It also encouraged younger writers by offering space for scientific reviews in its society publication, *BNA Bulletin*, and by organising and contributing prizes for the best undergraduate and postgraduate theses during the year, and for the best articles entered for the *National Brain Science Writing Prize*.

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

TRUSTEES' REPORT

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

The BNA renewed its affiliation to FENS, IBRO and to the Biosciences Federation during this period, paying subscriptions to these societies on behalf of all its members. Committee members attended the BSF members' meeting and AGM during the spring, and attended FENS and IBRO Council meetings during the year as well.

The BNA Committee met four times (December, March, June and September) and the Directors met twice (April and June). Professor Bruno Frenguelli and Dr Lucy Annett were nominated to the committee in the summer and attended their first committee meeting in September, after the retirement of Prof Andrew King and Dr Narender Ramnan. Dr Ramnan was co-opted for a further two years, however, so that he can oversee the special workshops in neuroimaging planned for the national meeting in the spring, 2009. Professor Richard Frackowiak retired as President in January 2007, and was replaced by Professor Graham Collingridge, elected by the committee during the previous year. Dr Debbie Dewar also retired as Honorary Secretary at the AGM in April in Harrogate, and was replaced by Professor Colin Ingram, also elected by the committee. Dr Dewar agreed to remain a Director for another two years. Similarly, Dr Mike O'Neill who retired as co-opted corporate representative in the autumn also agreed to remain a director for a further two years.

Financial Review

The financial position of the Company is summarised as follows -	30 09 07 £	30.09.06 £
Net (outgoing) / incoming resources for the year	50,351	(109)
Net investment (deficit) / gains	(2,146)	1,911
	-----	-----
Net movement in funds	48,205	1,802
	-----	-----
Net assets at 30 th September 2007 / 2006	388,196	339,991
	-----	-----

Investment Powers, Policy and Performance

The trustees' investment powers are governed by the Memorandum and Articles of Association, which permits the charity's funds to be invested in securities or property as may be thought fit, subject to conditions and consents as laid down in the Association's governing documents.

The trustees' policy is to optimise income on temporarily invested funds and to maintain a balanced portfolio of long-term investments.

The charity's investments have continued to be managed in conformity with our policy and Trust Deed, and their performance for the year has been in line with expectations.

The directors and committee agreed to dispose of the charity's holding in the Framlington Health Fund and sanctioned a further contribution of £100K to Charifund as part of its investment strategy during this period.

Reserves

Our policy is to continue to build up reserves by means of annual operating surpluses and judicious management of our investment assets, supplemented by direct appeals to corporate sponsors. Unrestricted funds at 30th September 2007 amounted to £382,696.

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

TRUSTEES' REPORT

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

Responsibilities of the Trustees

The Charities Act requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity at the end of the year and of the surplus or deficiency for the year then ended


In preparing those financial statements, the trustees are required to select suitable accounting policies, as described on page 7, and then apply them on a consistent basis, making judgements and estimates that are prudent and reasonable. The Trustees must also prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 1993. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Risk Management

The trustees examine the major risks that the charity faces each financial year. Potential risks, once identified, will be monitored and these risks controlled to mitigate any impact that they may have on the Association in the future.

Signed on behalf of the Trustees



Honorary Treasurer

Approved by the trustees on 25th June 2008

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES

We have audited the financial statements on pages 7 to 13, which comprise the Statement of Financial Activities, the balance sheet and the related notes. These financial statements have been prepared in accordance with the accounting policies set out therein.

This report is made solely to the charity's trustees, as a body, in accordance with Section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditors

The responsibilities of the trustees (who are also the directors of British Neuroscience Association Limited for the purposes of company law) for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards are set out in the Statement of Trustees' Responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the information given in the Trustees' Report is not consistent with the financial statements, if the charity has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and transactions with the charity is not disclosed.

We read other information contained in the Trustees' Report, and consider whether it is consistent with the audited financial statements. We consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements. Our responsibilities do not extend to any other information.


Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charitable company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming an opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the charitable company's affairs as at 30th September 2007 and of its incoming resources and application of resources, including its income and expenditure, for the period then ended and have been properly prepared in accordance with the Companies Act 1985.


Verinder and Associates
Registered Auditor
Chartered Accountants

25th June 2008

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

STATEMENT OF FINANCIAL ACTIVITIES

(Including Income and Expenditure Account)

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

	Notes	Unrestricted Funds £	Restricted Funds £	Total Funds 2007 £	Total Funds 2006 £
Incoming Resources					
Incoming resources from generated funds:					
<i>Voluntary Income</i>					
Donations and Sponsorship		15,203	-	15,203	7,500
<i>Activities for generating funds</i>					
Advertising and Mailing List Income		1,007	-	1,007	1,050
Brain Facts Booklet		401	-	401	446
<i>Investment Income</i>					
Bank Interest and Dividends Received		11,615	-	11,615	5,697
Incoming resources from charitable activities:					
Subscriptions from Members		75,427	-	75,427	66,831
Conference Income		201,922	-	201,922	-
One Day Meeting Income		39,778	-	39,778	-
Other incoming resources		90	-	90	202
		<hr/>	<hr/>	<hr/>	<hr/>
Total Incoming Resources		345,443	-	345,443	81,726
		<hr/>	<hr/>	<hr/>	<hr/>
Resources expended					
Cost of generating funds	2	5,862	-	5,862	2,499
Charitable Activities	3	275,713	-	275,713	69,556
Governance costs	4	13,517	-	13,517	9,780
		<hr/>	<hr/>	<hr/>	<hr/>
Total resources expended		295,092	-	295,092	81,835
		<hr/>	<hr/>	<hr/>	<hr/>
Net (outgoing) / incoming resources before other recognised gains					
Realised and unrealised gains and losses on investment assets	7	(2,146)	-	(2,146)	1,911
		<hr/>	<hr/>	<hr/>	<hr/>
Net movement in funds		48,205	-	48,205	1,802
		<hr/>	<hr/>	<hr/>	<hr/>
Balances brought forward at 1 st October 2006		334,491	5,500	339,991	338,189
		<hr/>	<hr/>	<hr/>	<hr/>
Balances carried forward at 30th September 2007	10	382,696	5,500	388,196	339,991
		<hr/>	<hr/>	<hr/>	<hr/>

The statement of financial activities includes all gains and losses recognised in the year
All incoming resources and resources expended derive from continuing activities

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

BALANCE SHEET

AS AT 30TH SEPTEMBER 2007

	<u>Note</u>	2007		2006	
		£	£	£	£
<u>FIXED ASSETS</u>					
Tangible Fixed Assets	6		650		370
Investments	7		272,928		193,546
			<hr/>		<hr/>
			273,578		193,916
 <u>CURRENT ASSETS</u>					
Debtors	8	1,798		14,779	
Cash at Bank		154,977		159,908	
			<hr/>		<hr/>
		156,775		174,687	
 <u>CREDITORS: Amounts Falling Due Within One Year</u>					
	9	(42,157)		(28,612)	
			<hr/>		<hr/>
Net Current Assets			114,618		146,075
			<hr/>		<hr/>
NET ASSETS			388,196		339,991
			<hr/>		<hr/>
 <u>Funds</u>					
Unrestricted Funds	10		382,696		334,491
Restricted Funds	10		5,500		5,500
			<hr/>		<hr/>
			388,196		339,991
			<hr/>		<hr/>

Approved by the Board of Trustees on 25th June 2008 and signed on its behalf by



BRITISH NEUROSCIENCE ASSOCIATION LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

1. Accounting Policies

The following accounting policies have been used consistently in dealing with items which are considered material in relation to the financial statements

a) Basis of accounting

The financial statements have been prepared under the historical cost convention and comply with the Companies Act 1985. The financial statements have been prepared in accordance with Statement of Recommended Practice (SORP), 'Accounting and Reporting by Charities Statement of recommended practice' published in March 2005 and applicable accounting standards. Where appropriate comparative figures have been restated.

b) Fund Accounting

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the charitable objectives of British Neuroscience Association Limited.

Restricted income funds are funds subject to specific restrictions imposed by donors or by the purpose of the appeal. The purpose and use of the restricted funds is set out in the notes to the financial statements.

c) Investments

Investments are included at market value.

Realised and unrealised gains and losses on revaluations are included in the statement of financial activities for the year.

d) Depreciation

Depreciation is calculated to write down the cost of all tangible fixed assets over their estimated useful lives, by equal annual installments on a straight line basis as follows:

Computer Equipment	30% Straight Line
---------------------------	--------------------------

e) Income

All income is accounted for as soon as British Neuroscience Association Limited has entitlement to the income and there is certainty of receipt and the amount is quantifiable.

Donations and Sponsorships are accounted for in the accounting period in which they are received.

Investment income comprises interest receivable on bank deposits and dividends received during the accounting year.

Grants are accounted for in the accounting year in which they are received. If appropriate, the income is deferred in the balance sheet.

Income derived from other activities is accounted for in the accounting period in which it is receivable.

f) Resources Expended

All expenditure is accounted for on an accruals basis and has been listed under headings that aggregate all the costs related to that activity. Where costs cannot be directly attributed they have been allocated to activities on a basis consistent with the use of the resources.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between expense headings on the basis of time spent.

Governance costs are those incurred in connection with the management of British Neuroscience Association Limited's assets, organisational administration and compliance with constitutional and statutory requirements.

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

2. Costs of generating funds

	Year Ended 30.09.07 £	Period Ended 30.09.06 £
Advertising and Promotion	1,639	-
Apportionment of Support Costs (Note 5)	4,223	2,499
	<hr/>	<hr/>
	5,862	2,499
	<hr/>	<hr/>

3. Charitable Expenditure

	£	£
BNA Bulletin Production Costs	11,400	8,355
Bursaries	4,380	7,100
Local Branch Expenses	3,792	3,655
One Day Meeting Expenses	41,836	4,930
Conference Expenses	133,432	-
Donations and Prizes	1,550	-
Subscriptions and Memberships	7,523	3,031
Apportionment of Support Costs (Note 5)	71,800	42,485
	<hr/>	<hr/>
	275,713	69,556
	<hr/>	<hr/>

4. Governance Costs

	£	£
Committee Expenses	2,133	992
Accountancy and Audit fees	2,937	3,408
Legal and Professional fees	-	382
Apportionment of Support Costs (Note 5)	8,447	4,998
	<hr/>	<hr/>
	13,517	9,780
	<hr/>	<hr/>

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

5 Analysis of Support Costs

	Charitable Activities £	Cost of Generating funds £	Governance £	Total 30 09 07 £	Total 30 09 06 £
Support Cost					
Executive Costs	45,038	2,649	5,299	52,986	28,578
Rent	3,400	200	400	4,000	2,333
Telephone	25	2	3	30	215
Printing, Postage & Stationery	5,636	331	663	6,630	3,735
Secretarial Assistance	13,418	789	1,579	15,786	12,223
Sundry Expenses	338	20	39	397	582
Bank Charges	2,695	159	317	3,171	1,001
Travel and Subsistence	822	48	97	967	1,089
Depreciation of Fixed Assets	428	25	50	503	183
Bank Interest	-	-	-	-	43
	71,800	4,223	8,447	84,470	49,982

British Neuroscience Association Limited allocates its support costs as shown above and then further apports those costs between the activities undertaken the charity Support costs are allocated on a basis consistent with the use of resources

6. Tangible Fixed Assets

	Computer Equipment £	Total £
Cost or Valuation		
At 1 st October 2006	866	866
Additions	783	783
	1,649	1,649
At 30th September 2007		
Depreciation		
At 1 st October 2006	496	496
Additions	503	503
	999	999
At 30th September 2007		
Net Book Value		
At 30 th September 2007	650	650
	370	370
At 30th September 2006		

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

<u>7 Investments</u>	2007	2006
	£	£
UK quoted investments	272,928	193,546
	<hr/>	<hr/>
Movement in market value		
	£	£
Market value at 1 st October 2006	193,546	91,635
Additions	100,000	100,000
Disposals	(18,472)	-
Net Investment Gains	(2,146)	1,911
	<hr/>	<hr/>
Market Value at 30 th September 2007	272,928	193,546
	<hr/>	<hr/>
Analysis of UK Quoted Investments	£	£
Framlington Health Fund Accumulated Units	-	18,350
Framlington Exempt Balance Accumulated Units	47,732	43,306
Scottish Widows UK Sheltered Growth Units	30,139	29,648
M & G Investments Charifund	147,226	51,840
M & G Investments Charibond	47,831	50,402
	<hr/>	<hr/>
	272,928	193,546
	<hr/>	<hr/>
<u>8 Debtors</u>	£	£
Trade Debtors	-	2,530
Prepayments and Accrued Income	1,798	12,249
	<hr/>	<hr/>
	1,798	14,779
	<hr/>	<hr/>
<u>9. CREDITORS: Amounts falling due within one year</u>	£	£
Bank Loans and Overdrafts	1,157	1,267
Trade Creditors	38,063	3,537
Other Taxes and Social Security Costs	-	1,627
Accruals and Deferred Income	2,937	22,181
	<hr/>	<hr/>
	42,157	28,612
	<hr/>	<hr/>

BRITISH NEUROSCIENCE ASSOCIATION LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2007

10. Total Funds

	Balance at 1st October 2006 £	Movement in resources		Balance at 30th September 2007 £
		Incoming £	Outgoing £	
Unrestricted – General	334,491	345,443	(297,238)	382,696
Restricted - Wolstencroft Fund	5,500	-	-	5,500
	<hr/>	<hr/>	<hr/>	<hr/>
	339,991	345,443	(297,238)	388,196
	<hr/>	<hr/>	<hr/>	<hr/>

11. Analysis of assets between funds

Funds balances at 30th September 2007 are represented by:

	Unrestricted Funds £	Restricted Funds £	Total Funds £
Fixed Assets	650	-	650
Investments	272,928	-	272,928
Debtors	1,798	-	1,798
Cash at bank	149,477	5,500	154,977
Creditors	(42,157)	-	(42,157)
	<hr/>	<hr/>	<hr/>
	382,696	5,500	388,196
	<hr/>	<hr/>	<hr/>